U.S. Markets close in 1 hr 21 mins

IVERIC bio, Inc. (ISEE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.23-0.02 (-0.15%)
As of 02:39PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.25
Bid13.23 x 800
Ask13.24 x 800
Day's Range12.90 - 13.36
52 Week Range8.37 - 19.34
Avg. Volume2,088,950
Market Cap1.517B
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • InvestorPlace

    7 Cheap Biotech Stocks to Buy Now

    Biopharmaceutical companies have been struggling since 2021 and that narrative isn’t immediately changing. However, not every firm deserves this fate. In fact, investors can find great opportunities with “cheap” biotech stocks to buy now. There are many reasons for investor pessimism that could soon ease. For instance, drug innovation has stagnated in 2022. Companies also haven’t been able to announce as many positive clinical readouts to build confidence. These both could change in a jiffy if a

  • Motley Fool

    IVERIC bio, Inc. (ISEE) Q2 2022 Earnings Call Transcript

    Representing IVERIC bio today are Mr. Glenn Sblendorio, chief executive officer; Dr. Pravin Dugel, president; Keith Westby, chief operating officer; David Carroll, chief financial officer; Dr. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.

  • Benzinga

    IVERIC bio Shares Jump On Debt Financing To Fund Zimura Launch

    IVERIC bio Inc (NASDAQ: ISEE) has entered into a debt financing facility with Hercules Capital Inc (NYSE: HTGC) and Silicon Valley Bank, providing the company with a total borrowing capacity of up to $250 million in non-dilutive debt financing. "We are grateful to secure this non-dilutive financing as it further strengthens our balance sheet and provides financial flexibility as we look to fund the potential commercial launch of Zimura (avacincaptad pegol) in geographic atrophy (GA) in the U.S.